- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03493737
Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma (ADHOMY)
Cost-Utility Evaluation Comparing Hospital Versus Home-Based Bortezomib in Multiple Myeloma: The ADHOMY Study
Bortezomib needs repetitive visits at hospital for injections. Hospital-at-Home (HaH) might be an attractive and suitable alternative in this situation.
This study aim to perform a cost-utility analysis of two different strategies in several HaH structures within the Grand Est region in France.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Bortezomib is a standard therapy of newly-diagnosed multiple myeloma and is also approved for relapsing disease, requiring the patients to travel to the outpatient-hospital (OH) once a week for several months. Hospital-at-Home (HaH) might be an attractive and suitable alternative in this situation.
This study aim to perform a cost-utility analysis of two different strategies in several HaH structures within the Grand Est region in France: exclusive hospital-based Bortezomib administration versus combined administration in both OH and HaH.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Vandœuvre-lès-Nancy, Frankrig, 54500
- CHRU Nancy
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Minimum age 18
- Enrolled in a social security scheme
- Diagnosis of multiple myeloma in first line or relapse
- Treatment plan including Bortezomib, adopted in a multidisciplinary meeting in a department of Hematology in Nancy (main investigator), Reims, Strasbourg University Hospitals or Metz-Thionville and Mulhouse local state-run hospitals
- The patients must have agreed to the treatment protocol and to take IV or PO associated drugs prescribed in addition to Bortezomib
The patients must meet the 2003 eligibility criteria of the National Agency for Accreditation and Evaluation in Health (ANAES) for chemotherapy at home:
- Absence of severe adaptive or psychological disorders, ability to understand the protocol
- Absence of cognitive impairment
- Availability and agreement of the attending physician
- Home safety and hygiene
- Do not decline to participate in the research and share their personal data
Exclusion Criteria:
- Already participating in another trial
- Have a follow-up and/or treatment for another condition requiring a particular care during the Bortezomib treatment period
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
HaH (Hospital-at-Home)
Bortezomib is injected at Outpatient hospital at day 1 and at Home at further day of cycles
|
Quality of life surveys by EQ-5D and QLQ-C30
|
OH (Outpatient Hospital)
Bortezomib is always injected at Outpatient hospital
|
Quality of life surveys by EQ-5D and QLQ-C30
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Cost therapy assessment
Tidsramme: 10 months follow-up per patient
|
Cost therapy assessment including direct medical costs, non-medical costs and indirect costs, investigated from the French Health Insurance perspective and expressed in Euro.
|
10 months follow-up per patient
|
EQ-5D questionnaire
Tidsramme: 10 months follow-up per patient
|
10 months follow-up per patient
|
|
QLQ-C30 questionnaire
Tidsramme: 10 months follow-up per patient
|
an oncology-specific instrument
|
10 months follow-up per patient
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjerte-kar-sygdomme
- Karsygdomme
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Hæmatologiske sygdomme
- Hæmoragiske lidelser
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Myelomatose
- Neoplasmer, Plasmacelle
Andre undersøgelses-id-numre
- 2018-A00103-52
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Quality of life surveys
-
Seoul National University HospitalTrukket tilbageDepression | Postoperative komplikationer | Angst | MestringsadfærdKorea, Republikken
-
Memorial Sloan Kettering Cancer CenterAfsluttetAscitesForenede Stater
-
Latin American Cooperative Oncology GroupRoche Pharma AG; EVA - Grupo Brasileiro de Tumores GinecológicosAfsluttet
-
University of FloridaAfsluttet
-
World Vision CanadaRyerson University; World Health Organization; Global Affairs Canada; Ministry...AfsluttetDiarré | Malaria | Akut luftvejsinfektion
-
University Hospital, Strasbourg, FranceAfsluttetKirurgisk indgreb | MindreFrankrig
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustAfsluttet
-
Akdeniz UniversityAfsluttet
-
Beijing Tsinghua Chang Gung HospitalRekrutteringPostoperative komplikationer | Cerebrovaskulær ulykke | Større uønskede hjertehændelser | ModellerKina
-
Ondokuz Mayıs UniversitySamsun Education and Research HospitalAfsluttet